 |
|
Leukemia Trial Results
1. Allogeneic (Donor) Stem-Cell Transplant Boosts Survival in Ph-Negative, Standard-Risk ALL
(Posted: 01/07/2008) - In the largest-ever clinical trial of treatment for adults with acute lymphoblastic leukemia (ALL), patients with standard-risk, Philadelphia-chromosome-negative ALL lived significantly longer after chemotherapy-induced first remission when they received allogeneic (donor) stem-cell transplantation instead of continued chemotherapy, according to a Nov. 29, 2007, report issued by Blood.
2. Dasatinib and Nilotinib Both Effective for CML When Imatinib Won't Work
(Posted: 10/31/2007) - Two new targeted drugs - dasatinib (Sprycel®) and nilotinib (Tasigna®) - are effective in most patients with chronic myelogenous leukemia who cannot take or who have become resistant to imatinib (Gleevec®), according to two 2007 reports in the journal Blood.
3. Dasatinib Effective Against Difficult-to-Treat Acute Lymphoblastic Leukemia
(Posted: 06/01/2007) - The multitargeted drug, dasatinib (Sprycel) may be extremely beneficial in adult patients with a form of acute lymphoblastic leukemia (ALL) who have developed resistance or do not respond to another targeted agent, imatinib mesylate (Gleevec), according to the May 11, 2007, issue of the journal Blood.
4. Dasatinib Effective in Blast-Crisis Chronic Myeloid Leukemia
(Posted: 05/08/2007) - Dasatinib can induce lasting hematologic and cytogenetic responses in patients with the blast-crisis phase of chronic myeloid leukemia, according to the April 15, 2007, issue of Blood.
5. Low-Dose Cytarabine Improves Survival of Older Patients with Leukemia
(Posted: 03/27/2007) - Low doses of the chemotherapy drug cytarabine increased overall survival in patients with acute myeloid leukemia who were not healthy enough to receive the standard treatment of high-dose, intensive chemotherapy, according to the March 15, 2007, issue of the journal Cancer.
1 2 3 4 Next >
|
|
|
